Justin DaSilva

Justin DaSilva

Auto-generated profile, based on publicly available information

Justin DaSilva

Laboratory of Retrovirology, The Rockefeller University, New York, NY 2

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Nature
Verified
Journal Article
Closed access
ZWZijun Wang
Zijun Wang
FSFabian Schmidt
Fabian Schmidt
YWYiska Weisblum
Yiska Weisblum
FMFrauke Mücksch
Frauke Mücksch
CBChristopher O. Barnes
Christopher O. Barnes
MNMichel C. Nussenzweig
Michel C. Nussenzweig

7 October 2021 in Nature
Verified
Journal Article
Open access
PDF file
ACAlice Cho
Alice Cho
FMFrauke Mücksch
Frauke Mücksch
DSDennis Schaefer-Babajew
Dennis Schaefer-Babajew
ZWZijun Wang
Zijun Wang
SFShlomo Finkin
Shlomo Finkin
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern1. As a result, vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines produces high levels of plasma neutralizing activity against all variants tested1,2. Here we examine memory B cell evolution five months after vaccination with either Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) mRNA vaccine in a cohort of SARS-CoV-2-naive individuals. Between prime and boost, memory B cells produce antibodies that evolve increased neutralizing activity, but there is no further increase in potency or breadth thereafter. Instead, memory B cells that emerge five months after vaccination of naive individuals express antibodies that are similar to those that dominate the initial response. While individual memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination, the overall neutralizing potency of plasma is greater following vaccination. These results suggest that boosting vaccinated individuals with currently available mRNA vaccines will increase plasma neutralizing activity but may not produce antibodies with equivalent breadth to those obtained by vaccinating convalescent individuals.

20 September 2021 in Nature
Verified
Journal Article
Closed access
PDF file
FSFabian Schmidt
Fabian Schmidt
YWYiska Weisblum
Yiska Weisblum
MRMagdalena Rutkowska
Magdalena Rutkowska
DPDaniel Poston
Daniel Poston
JDJustin DaSilva
Justin DaSilva
PBPaul D. Bieniasz
Paul D. Bieniasz

23 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZWZijun Wang
Zijun Wang
PZPengcheng Zhou
Pengcheng Zhou
FMFrauke Mücksch
Frauke Mücksch
ACAlice Cho
Alice Cho
TTTarek Ben Tanfous
Tarek Ben Tanfous
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Individuals who receive a third mRNA vaccine dose show enhanced protection against severe COVID-19, but little is known about the impact of breakthrough infections on memory responses. Here, we examine the memory antibodies that develop after a third or fourth antigenic exposure by Delta or Omicron BA.1 infection, respectively. A third exposure to antigen by Delta breakthrough increases the number of memory B cells that produce antibodies with comparable potency and breadth to a third mRNA vaccine dose. A fourth antigenic exposure with Omicron BA.1 infection increased variant-specific plasma antibody and memory B cell responses. However, the fourth exposure did not increase the overall frequency of memory B cells or their general potency or breadth compared to a third mRNA vaccine dose. In conclusion, a third antigenic exposure by Delta infection elicits strain-specific memory responses and increases in the overall potency and breadth of the memory B cells. In contrast, the effects of a fourth antigenic exposure with Omicron BA.1 are limited to increased strain-specific memory with little effect on the potency or breadth of memory B cell antibodies. The results suggest that the effect of strain-specific boosting on memory B cell compartment may be limited.

8 September 2022 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
DGDaniel Gonçalves-Carneiro
Daniel Gonçalves-Carneiro
EMEmily Mastrocola
Emily Mastrocola
XLXiao Lei
Xiao Lei
JDJustin DaSilva
Justin DaSilva
YCYoke Fun Chan
Yoke Fun Chan
PBPaul D. Bieniasz
Paul D. Bieniasz
Attenuation of a virulent virus is a proven approach for generating vaccines but can be unpredictable. For example, synonymous recoding of viral genomes can attenuate replication but sometimes results in pleiotropic effects that confound rational vaccine design. To enable specific, conditional attenuation of viruses, we examined target RNA features that enable zinc finger antiviral protein (ZAP) function. ZAP recognized CpG dinucleotides and targeted CpG-rich RNAs for depletion, but RNA features such as CpG numbers, spacing and surrounding nucleotide composition that enable specific modulation by ZAP were undefined. Using synonymously mutated HIV-1 genomes, we defined several sequence features that govern ZAP sensitivity and enable stable attenuation. We applied rules derived from experiments with HIV-1 to engineer a mutant enterovirus A71 genome whose attenuation was stable and strictly ZAP-dependent, both in cell culture and in mice. The conditionally attenuated enterovirus A71 mutant elicited neutralizing antibodies that were protective against wild-type enterovirus A71 infection and disease in mice. ZAP sensitivity can thus be readily applied for the rational design of conditionally attenuated viral vaccines.

1 July 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ACAlice Cho
Alice Cho
FMFrauke Mücksch
Frauke Mücksch
ZWZijun Wang
Zijun Wang
TTTarek Ben Tanfous
Tarek Ben Tanfous
JDJustin DaSilva
Justin DaSilva
MNMichel C. Nussenzweig
Michel C. Nussenzweig
The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either of the two available mRNA vaccines. In addition, Ad.26.COV.2 has been less effective in protection against severe disease during the Omicron surge. Here, we examined the memory B cell response to single-dose Ad.26.COV.2 vaccination. Compared with mRNA vaccines, Ad.26.COV.2 recipients had significantly lower numbers of RBD-specific memory B cells 1.5 or 6 mo after vaccination. Despite the lower numbers, the overall quality of the memory B cell responses appears to be similar, such that memory antibodies elicited by both vaccine types show comparable neutralizing potency against SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 variants. The data help explain why boosting Ad.26.COV.2 vaccine recipients with mRNA vaccines is effective and why the Ad26.COV2.S vaccine can maintain some protective efficacy against severe disease during the Omicron surge.